Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate anti-counterfeiting bill would give firms statutory damages up to $1 mil..

This article was originally published in The Gray Sheet

Executive Summary

SENATE ANTI-COUNTERFEITING BILL WOULD ALLOW STATUTORY DAMAGES for manufacturers as an alternative remedy to actual losses in sales from counterfeit goods. Introduced by Senate Judiciary Committee Chair Orrin Hatch (R-Utah) on Aug. 9, S 1136 would allow plaintiffs to claim "an award of statutory damages for any such use in the amount of (1) not less than $500 or more than $100,000 per counterfeit mark per type of goods or services," or "(2) if the court finds that the use of the counterfeit mark was willful, not more than $1 mil. per counterfeit mark."

You may also be interested in...



Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.

Swisse Supplements Take Bigger Slice Of Chinese Market

Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.

Novartis Draws Out Its APPLAUSE

Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel